Vazyme(SH:688105) Xin Lang Cai Jing·2025-11-13 01:34Group 1 - The core viewpoint of the news is that NuoVas has experienced fluctuations in its financing activities, with a net financing outflow on November 12, indicating potential investor caution [1] - On November 12, NuoVas had a financing buy-in amount of 3.25 million yuan and a financing repayment of 4.92 million yuan, resulting in a net financing buy-in of -1.67 million yuan [1] - As of November 12, the total financing and securities lending balance for NuoVas was 92.81 million yuan, with a financing balance of 91.97 million yuan, accounting for 0.97% of the circulating market value [1] Group 2 - NuoVas, established on March 16, 2012, is a biotechnology company focused on the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [2] - For the period from January to September 2025, NuoVas reported an operating income of 952 million yuan, a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.62 million yuan, down 63.57% year-on-year [2] - As of September 30, NuoVas had 9,447 shareholders, an increase of 9.90% from the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 3 - Since its A-share listing, NuoVas has distributed a total of 731 million yuan in dividends, with 611 million yuan distributed over the past three years [3]